Global Uranium-230 Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Uranium-230 market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
In 2025, global Uranium-230 production was approximately 43 grams, with an average global market price of around $124,000 per gram. That year, total global production capacity for Uranium-230 reached 120 grams, and the industry's average gross profit margin stood at 35%. Uranium-230 is an artificial radioactive isotope of uranium with an atomic number of 92 and a mass number of 230. It has a half-life of approximately 20.8 days and primarily decays via alpha emission into thorium-226 (which has a half-life of about 30.6 minutes), subsequently releasing multiple alpha particles as it proceeds along the decay chain. Due to the high linear energy transfer and short tissue range of alpha particles, uranium-230 and its daughter isotope, thorium-226, are being investigated for targeted alpha therapy; they are particularly promising for treating micrometastases, residual lesions, and disseminated cancer cells. Uranium-230 can also serve as a "parent nuclide" in radionuclide generators, allowing for the periodic separation of thorium-226 and thereby providing a localized supply of short-lived therapeutic radionuclides. However, uranium-230 remains in the research stage regarding production processes, chelation chemistry, and preclinical applications, and a routine commercial market for this medical isotope has not yet been established.
The upstream segment of the industry chain primarily encompasses high-purity thorium-232 metal targets or protactinium-231 targets, medium-to-high-energy proton accelerators, irradiation target stations, hot cells, remote handling equipment, radiation shielding systems, and materials for ion exchange and solvent extraction. One production route with a solid research foundation involves proton irradiation of thorium-232: the ^232Th(p,3n)^230Pa reaction first produces protactinium-230 (half-life ~17.4 days), which then decays into uranium-230. Another route involves proton irradiation of the scarce protactinium-231 target to directly produce uranium-230 via the ^231Pa(p,2n)^230U reaction. The thorium target route offers relatively good raw material availability and potential for co-production with other medical radionuclides like actinium-225; however, it generates fission products as well as other uranium and protactinium isotopes, necessitating highly selective separation processes. Key upstream technical challenges lie in high-energy proton beam technology, the fabrication of radioactive thorium targets, the control of protactinium and uranium impurities, target material recovery, and automated operations within highly radioactive environments. The midstream sector of the industry chain primarily comprises national laboratories, medical isotope production centers, radiochemistry platforms, and radiopharmaceutical R&D institutions; these entities are responsible for rapidly separating Protactinium-230 (Pa-230) and Uranium-230 (U-230) from irradiated thorium targets and converting the products into chemical forms suitable for generator loading or radiolabeling. Publicly available research has established dual-column ion-exchange and extraction chromatography processes capable of simultaneously recovering high-purity U-230 and Pa-230 from proton-irradiated Thorium-232 (Th-232) targets and their fission products. U-230 can be further processed into a U-230/Th-226 generator, utilizing the chemical differences between the two elements to repeatedly separate Thorium-226 (Th-226); such systems have achieved Th-226 separation yields exceeding 96%, delivering the product in a solution form suitable for subsequent chelation reactions. Another core midstream task involves developing chelating agents capable of stably binding uranyl ions in vivo to prevent U-230 from dissociating from its targeting vector and depositing in non-target organs; several multidentate ligands have already demonstrated favorable complexation stability in *in vitro* and animal studies. The downstream sector primarily encompasses oncology radiopharmaceutical developers, nuclear medicine centers, preclinical research institutions, and national nuclear medicine laboratories. U-230 can be directly conjugated to antibodies, peptides, or small-molecule targeting vectors for use as an alpha-emitting therapeutic radionuclide with a relatively long half-life; alternatively, it can serve as the parent isotope in a U-230/Th-226 generator, allowing for the on-demand separation of short-lived Th-226 at hospitals or regional radiopharmacies. The U-230/Th-226 decay chain generates multiple alpha particles in succession, theoretically delivering a high total radiation dose to target cells, which makes it a promising candidate for treating refractory tumors, micrometastases, and residual disease. Its industrialization remains constrained by factors such as the complexity of uranium coordination chemistry, the potential for in vivo migration of daughter nuclides, limited production facilities, insufficient dosimetry data, and the lack of mature GMP manufacturing and regulatory standards; in the short term, demand is primarily driven by research batches and preclinical projects, while the ultimate development of a commercial market depends on stable chelation systems, animal safety profiles, and clinical evidence from human studies.
The surging interest in targeted alpha therapy is the primary driver behind the R&D and industrialization of Uranium-230. Characterized by high linear energy transfer (LET) and a short tissue range, alpha particles induce irreparable DNA double-strand breaks within a localized area, making them particularly suitable for treating micrometors, disseminated lesions, and micrometastases. With a half-life of approximately 20.8 days, Uranium-230 serves both as a potential therapeutic radionuclide and as the parent isotope for Thorium-226; the Uranium-230/Thorium-226 decay chain releases multiple alpha particles, theoretically offering high therapeutic efficacy per unit of radionuclide. Amidst supply shortages and high costs associated with alpha-emitters like Actinium-225, research institutions are evaluating candidates suitable for large-scale production, thereby keeping Uranium-230 in the spotlight. However, its therapeutic value requires further validation through systematic studies on animal efficacy, dosimetry, and toxicology, and it has not yet reached the stage of mature clinical application.
The Uranium-230/Thorium-226 generator model represents its most distinctive application pathway. Thorium-226 has a half-life of only about 30.6 minutes, making long-distance distribution from centralized production facilities impractical; conversely, the longer-lived Uranium-230 can be loaded into a generator to allow for the on-demand separation of Thorium-226 at regional nuclear medicine centers or radiopharmacies. This model—combining the transport of a long-lived parent isotope with the on-site preparation of a short-lived daughter isotope—promises to overcome the supply radius limitations associated with short-lived alpha-emitters while facilitating repeated elutions and continuous research use. Publicly available research has already confirmed the feasibility of separation using the Uranium-230/Thorium-226 generator and has led to the development of rapid elution and "reverse generator" processes; consequently, the industry's focus is likely to shift gradually from the standalone sale of Uranium-230 stock solutions toward generator assemblies, automated separation modules, and supporting quality control services.
Trends on the supply side will center on the co-production of Thorium targets, automated separation technologies, and the scaling up of production. Currently, a practically viable approach involves bombarding Thorium-232 with high-energy protons to first produce Protactinium-230, which then decays into Uranium-230. This route leverages existing medical isotope accelerator facilities and offers the potential for co-production with other thorium-target products—such as Actinium-225—thereby enhancing the overall utilization efficiency of both the proton beam and the target material. Research published in 2024 has established a process for the simultaneous separation of Protactinium-230 and Uranium-230 from proton-irradiated thorium targets and reported high recovery rates, indicating that the technology is advancing from basic feasibility studies toward reproducible batch production.
Report Scope
This report is a detailed and comprehensive analysis for global Uranium-230 market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Uranium-230 market size and forecasts, in consumption value ($ Million), sales quantity (Gram), and average selling prices (US$/g), 2021-2032
Global Uranium-230 market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Gram), and average selling prices (US$/g), 2021-2032
Global Uranium-230 market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Gram), and average selling prices (US$/g), 2021-2032
Global Uranium-230 market shares of main players, shipments in revenue ($ Million), sales quantity (Gram), and ASP (US$/g), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Uranium-230
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Uranium-230 market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include LANL, NIDC(DOE IP), RITVERC JSC, Uranium, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Uranium-230 market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market Segmentation
Market segment by Type
Purity: >95%
Purity: >98%
Market segment by Product Form
Uranium-230 Stock Solution
Uranium-230 Radiochemical Intermediate
Uranium-230/Thorium-226 Generator
Market segment by Production Route
Proton Irradiation of Thorium-232
Direct Proton Production from Protactinium-231
Proton Irradiation of Thorium Targets
Market segment by Quality Grade
Nuclear Physics Research Grade
Preclinical Research Grade
Market segment by Application
Cancer Treatment
Scientific Research
Major players covered
LANL
NIDC(DOE IP)
RITVERC JSC
Uranium
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Uranium-230 product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Uranium-230, with price, sales quantity, revenue, and global market share of Uranium-230 from 2021 to 2026.
Chapter 3, the Uranium-230 competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Uranium-230 breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Uranium-230 market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Uranium-230.
Chapter 14 and 15, to describe Uranium-230 sales channel, distributors, customers, research findings and conclusion.